Treatment of leg ulcers using placenta derived collagen biofabric

1. A method of treating a leg ulcer, comprising contacting said ulcer with a first collagen biofabric for a first period of two to five weeks, followed by contacting said ulcer with a second collagen biofabric for a second period of time, wherein said contacting with said first or second collagen biofabric improves at least one aspect of the leg ulcer, or prevents or reduces the worsening of at least one aspect of the leg ulcer, wherein the first and second collagen biofabric is decellularized and dehydrated prior to contacting said ulcer.

2. The method of claim 1 , wherein said first or second collagen biofabric is not artificially crosslinked.

3. The method of claim 1 , wherein said first or second collagen biofabric is not protease-treated during production.

4. The method of claim 1 , wherein said contacting for the first period of time or the second period of time is for a time sufficient for at least one aspect of the leg ulcer to measurably improve compared to a leg ulcer not contacted with the collagen biofabric.

5. The method of claim 1 , wherein said contacting for the first period of time or the second period of time is for a time sufficient to prevent or reduce the worsening of at least one aspect of a leg ulcer.

6. The method of claim 1 , wherein said leg ulcer is a venous leg ulcer, arterial leg ulcer, diabetic leg ulcer or decubitus ulcer.

7. The method of claim 1 , wherein said leg ulcer is a venous leg ulcer.

8. The method of claim 1 , wherein said first or second collagen biofabric is provided as a sheet or membrane.

9. The method of claim 1 , wherein said first or second collagen biofabric is provided as a netting or webbing.

10. The method of claim 1 , wherein said first or second collagen biofabric is mounted on a support.

11. The method of claim 10 , wherein said support is a bandage.

12. The method of claim 1 , wherein said contacting comprises placing the collagen biofabric on the leg ulcer so that substantially all of the surface area of the biofabric contacts the leg ulcer.

13. The method of claim 1 , wherein said first or second collagen biofabric additionally comprises a bioactive compound not naturally-occurring in the collagen biofabric, or present in a different concentration than in collagen biofabric to which the bioactive compound has not been added.

14. The method of claim 13 , wherein said bioactive compound is a small organic molecule, an antibiotic, pain medication, anti-inflammatory agent, cytokine, growth factor, enzyme inhibitor, kinase inhibitor, an anti-tumor agent, an anti-fungal agent, an anti-viral agent, an anti-infective agent, a wound sealant or a wound healing or sealing agent.

15. The method of claim 14 , wherein said wound healing or sealing agent is platelet-derived growth factor (PDGF), transforming growth factor (TGF), thymosin, hyaluronic acid, fibrin, fibronectin or thrombin, or a combination thereof.

16. The method of claim 1 , wherein the first period of time is four to five weeks.